Aluminum adjuvants have been used for a century in various vaccines due to its ability to 16 potentiate humoral immunity and safety records since 1920s. Manganese is an essential 17 micronutrient required for diverse biological activities in cells. We previously found that Mn 2+ is a 18 strong type I-interferon stimulator activating the cGAS-STING pathway. Herein we report that a 19 colloidal manganese salt (MnJ) is a potent adjuvant to induce both humoral and cellular immune 20 responses, particularly CTL activation. When administrated intranasally, MnJ was also a strong 21 mucosal adjuvant, inducing high levels of IgA antibodies. MnJ strongly promoted dendritic cell 22 maturation and antigen-specific T cell activation. Interestingly, IL-1/-18 induction and release by 23
administrations which may cause or manifest its adverse effects including increased IgE production 48 and neurotoxicity 8 . In addition, Alum mainly induces T helper 2 (TH2) cell response through 49 NLPR3 inflammasome activation 9-11 , but not TH1 or cytotoxic T-lymphocyte (CTL) response 1,12 . 50 Therefore, Alum is generally believed to be unable to elicit cellular immune responses that are 51 essential for virus or tumor vaccines. 52
In the past decades, however, the medical need for new adjuvants is increasing as (1) the 53 inflammasome. Instead, we found that N-acetyl-L-cysteine (NAC, a direct scavenger of ROS), 116 reduced L-glutathione (GSH, an intracellular thiol antioxidant), extracellular K + , or 2-APB (a 117 cytosolic Ca 2+ release inhibitor) all restrained Mn 2+ -induced inflammasome activation (Extended 118 Data Fig. 2a-g) . Using a modified culture medium, Hanks' Balanced Salt Solution Deletion of 119 PO4 3and CO3 2-(herein HBSSD), in which Mn 2+ and Ca 2+ did not form particles, we found that 120
Mn 2+ activated NLRP3 and pyroptosis were essentially independent of particle formation, which is 121 different from Ca 2+ (Extended Data Fig. 2h , i). mtDNA depletion (Extended Data Fig. 2j ) by 122 ethidium bromide 28 did not affect Mn 2+ -induced inflammasome activation either (Extended Data 123 Fig. 2k, l) . We thus concluded that Mn 2+ activated stronger NLRP3 inflammasome than Alum did. 124
Mn 2+ Activates Inflammasome without IL-1/-18 Production 125
Consistent with results from RNA-seq and qPCR (Fig. 1a, b) , Mn 2+ treatment did not induce 126 upregulation of Il1b and Il18 in both murine BMDCs and human monocyte derived dendritic cells 127 (Mo-DCs) (Fig. 3a) . Interestingly, Alum activated NLRP3 inflammasome in a similar way, neither 128 Mn 2+ nor Alum induced IL-1/18 production without LPS priming (Fig. 3b, c) . The same results 129 were obtained when human peripheral blood mononuclear cells (PBMCs) were treated with Mn 2+ 130 ( Fig. 3d ). Since clinical studies on various inflammatory diseases suggested the crucial role for 131
Given that Mn 2+ induced strong type I-IFN production and NLRP3 inflammasome activation, we 136 reasoned that Mn 2+ could be used as an adjuvant. To test this, we first immunized C57BL/6 mice 137 with LPS-free chicken ovalbumin protein (OVA) alone or OVA with different Mn 2+ solutions 138 intramuscularly (i.m.) or intranasally (i.n.) and measured OVA-specific antibodies. Surprisingly, 139 we found that only Mn 2+ in phosphate buffer saline (PBS), but not Mn 2+ in normal saline, 140 promoted antibody production (Extended Data Fig. 3a, b) . The difference was that Mn 2+ formed 141 particles in PBS but not in saline, suggesting that soluble Mn 2+ was unable to induce a local 142 immune response as expected. However, Mn 2+ particles in PBS tended to aggregate and precipitate 143 with time, thus lost its adjuvant activity (Extended Data Fig. 3c ). By screening various manganese 144 compounds, we generated jelly-like Mn 2+ colloids (MnJ, Mn Jelly) (Extended Data Fig. 3d ) 145 consisting of elongate nanoparticles approximately 2 × 2 × 6 nm in size (Extended Data Fig. 3e ). 146
MnJ was stable without aggregation in the following experiments. Its adjuvant effect was not 147 weakened after storage at -80 ºC for three weeks or longer, or even after freeze-148 drying/lyophilization (Extended Data Fig. 3f ). On the contrary, Alum vaccines are known to be 149 sensitive to freezing and thus hard to store or transport. Interestingly, MnJ triggered comparable 150 inflammasome activation (Extended Data Fig. 3g ), but stronger type I-IFN production than MnCl2 151 or Mn 2+ -PBS did (Extended Data Fig. 3h ), probably due to the facilitated transportation into cells 152 as nanoparticles 32, 33 . Compared to MnCl2, which disappeared within hours, MnJ had a much 153 longer muscle retention time up to 8 days at the site of injection, similar to Mn 2+ -PBS particles 154 (Extended Data Fig. 3i ). Splenocytes were isolated from OVA-immunized mice and stimulated 155 with major histocompatibility class II (MHC-II)-binding OVA peptide I-A b and MHC-I-binding peptide H-2K b to compare T cell activation. IFNγ induced in splenocytes from OVA-MnJ was 157 higher than OVA-Mn 2+ (Extended Data Fig. 3j ). Consequently, the adjuvant effect of MnJ was 158 significantly better than that of Mn 2+ -PBS (Extended Data Fig. 3a-c) . 159
We next evaluated the detailed adjuvant effect of MnJ. MnJ-adjuvanted antibody induction by 160 intramuscularly immunization showed dose-dependence and lasted for at least 6 months (Fig. 4a) . 161
Compared to three different Aluminum-containing adjuvants, MnJ induced much stronger 162 OVA-specific IgG1 production and CTL response (Fig. 4b) . We also compared MnJ with other 163 adjuvants including the complete Freund's adjuvant (CFA), incomplete Freund's adjuvant (IFA), 164 MF59 and polyetherimide (PEI). We found that MnJ adjuvant effect was even better than CFA (20 165 μg MnJ vs 50 μl CFA, i.m.) and MF59 (20 μg MnJ vs 50 μl MF59, i.m.) (Extended Data Fig. 3k, l) . 166
Also, MnJ boosted specific antibody production against different recombinant protein/peptide 167 antigens, including influenza A/PR8 hemagglutinin A1 peptide, haptenized experimental antigen 168 nitrophenol-conjugatd keyhole limpet hemocyanin (NP-KLH), HBV surface antigen (HBsAg) and 169 HBSS1 fusion protein (containing S (1-223 aa) and PreS1 (21-47 aa)) 34 , and inactivated 170 enterovirus type 71 (EV71) ( Fig. 4d ). Besides, intranasally immunization revealed that MnJ was 171 also a potent mucosal adjuvant, inducing high levels of IgA antibodies in lung, saliva, and serum 172 for a long time and as good as cholera toxin B (5 μg MnJ vs 10 μg CTB, i.n.) 35 (Fig. 4e, f) . 173
Importantly, compared to CFA-injected mice showing prominent swellings and granulomas with 174 one shoot (Extended Data Fig. 4a ), MnJ-injected mice displayed no visible side effects on injection 175 site, body weight, survival or different organs even after repeated administrations (3 shoots in 3 consecutive weeks) (Extended Data Fig. 4a -i), suggesting that MnJ is a safe adjuvant with good 177 biocompatibility. 178
MnJ Promotes Antigen Presentation and T Cell Responses 179
MF59 and Alum facilitate APCs to engulf antigens and transport them to draining lymph nodes 180 (dLNs), and also induce the differentiation of monocytes to dendritic cells (Mo-DCs) 36, 37 . So, we 181 significantly enhanced 12 and 24 h after MnJ immunization ( Fig. 5a ). Also, there was a significant 186 increase in the accumulation of Mo-DCs in mice immunized with antigen plus MnJ compared to 187 that in mice immunized with antigen alone (Fig. 5b) . 188
The capacity of MnJ to promote BMDC maturation was stronger compared with Mn 2+ , while Alum 189 did not have any effect (Fig. 5c ). In vivo, MnJ enhanced both CD4 + and CD8 + T cell proliferation, 190
whereas Alum only induced a weak CD4 + T cell proliferation ( Fig. 5d ). Splenocytes were next 191 isolated from OVA-immunized mice and stimulated with OVA to compare T cell activation. and IFNγ were highly induced in splenocytes from OVA-MnJ, but not OVA-Alum immunized 193 mice, whereas IL-4 and IL-10 were preferably produced via OVA-Alum immunization (Fig. 5e), 194 indicating that MnJ potently stimulated TH1 response, in addition to TH2 response. Accordingly, 195 in vivo cytotoxic assay showed that MnJ immunized mice generated very strong CTL activities in killing OVA-bearing cells, which was absent in Alum immunized mice (Fig. 5f ). MnJ also 197 promoted the formation of germinal center (GC) with significantly increased amounts of Tfh and 198 GC B cells ( Fig. 5g) . 199
Both cGAS-STING and NLRP3 Inflammasome Contribute to Adjuvant Activity of MnJ 200
Next,
Nlrp3 −⁄− mice produced diminished OVA-specific antibodies (Extended Data Fig. 5a ), 203
Tmem173 −⁄− Pycard −⁄− (double knockout, DKO) mice generated extremely decreased OVA-specific 204 antibodies ( Fig. 6a-c ), suggesting that both cGAS-STING and inflammasome contributed to MnJ 205 adjuvant effect. Further, Tmem173 −⁄− Nlrp3 −⁄− mice generated a bit more antibodies than 206
Tmem173 −⁄− Pycard −⁄− mice did ( Fig. 6a-b ), indicating the involvement of other ASC-dependent 207 inflammasome activation by MnJ. We also analyzed the expression of Dock2, which was reported 208 to be down-regulated in Pycard −⁄− but not Nlrp3 −⁄− or Caspase1 −⁄− mice 38 . Quantitative PCR 209 analysis confirmed the same expression of Dock2 mRNA in WT, Fig. 5b ). Consistently, 211
MnJ-promoted germinal center formation was impaired in the DKO (specifically referred to 212 Tmem173 −⁄− Pycard −⁄− in the following text) mice (Extended Data Fig. 5c ). In addition, 213
MnJ-induced OT-II CD4 + T cell proliferation disappeared in the DKO mice ( Fig. 6d ), along with 214 sharply reduced IFNγ and IL-2 production by peptide-stimulated splenic T cells ( Fig. 6e ). 215
Mn 2+ nor MnJ treatment did induce IL-1 or IL-18 expression in vitro or in vivo, we reasoned that 218
ASC-mediated inflammasome activation contributed to MnJ adjuvant activity by releasing other 219
DAMPs like uric acid 39 , but not by IL-1 or TNFα, consistent with previous reports that neither of 220 them was important for adjuvant effect 22,40 . However, CFA or Monophosphoryl Lipid A (MPLA) 221 induced antibody production did not change much among these mice (Extended Data Fig. 5d , e). 222
MnJ Is A Potent Adjuvant for Antiviral and Antitumor Vaccines 223
Next we tested the protection effect of MnJ adjuvanted vaccines against various viruses. 224
Formaldehyde-inactivated Vesicular stomatitis virus (VSV), Herpes simplex virus 1 (HSV-1) and 225
Vaccinia Virus (VACV) were used as vaccines. The optimal dose for each inactivated virus was 226 first determined (VSV and HSV i.m.; VACV i.n.) (Extended Data Fig. 6a-f ). MnJ greatly enhanced 227 the protection efficacy of inactivated virus by about 100 times, which is much better than Alum. 228
Consistently, virus titers were decreased by at least 10 3 times in MnJ immunized mice , 229
indicating that MnJ can be applied to all tested virus vaccines through either intramuscular or 230 intranasal immunization, with greatly reduced amounts of inactivated-virus needed for an adequate 231
protection. 232
We particularly tested MnJ in influenza vaccines. Mice immunized with virus protein HA1 (PR8) 233 plus MnJ (i.m. or i.n.) or HA1 plus CTB (i.n.) were completely protected from lethal H1N1 234 A/PR8/34 virus challenge, while Alum adjuvant only showed mild protection (Fig. 7g, h, . Importantly, MnJ enhanced the protection effect of inactivated PR8 vaccine by at 236 least 10 times (Fig. 7i ). Moreover, MnJ exhibited superior protection against heterologous 237 influenza viruses to mice immunized with MnJ-adjuvanted inactivated PR8 or HA1 protein, 238 followed by lethal H1N1 WSN or H3N2 challenge (Extended Data Fig. 6j ). 239
Finally, the adjuvant effect of MnJ on cancer vaccines was evaluated. Mice were immunized three 240 times before inoculated with melanoma cell B16-OVA subcutaneously. Tumor growth was greatly 241 suppressed in OVA-MnJ, but not OVA-Alum, immunized mice ( Fig. 7j , Extended Data Fig. 7a ), in 242 line with prominently improved survival (Fig 7k) and increased tumor-infiltrating CD4 + and CD8 + 243 T cells (Extended Data Fig. 7b , c), confirming CTL inducing activity of MnJ. In pulmonary 244 metastasis model, OVA-MnJ immunization greatly blocked lung metastases in the WT, but not 245 (Fig. 7l , m, Extended Data Fig. 7d ), which is consistent with the 246 proliferation of CD8 + OT-I T cells (Extended Data Fig. 7e ). In addition, OVA-specific antibody 247 production and CD8 + T cell activation analyzed by tetramer assays were only detected in 248
MnJ-OVA immunized WT mice ( Fig. 7n , Extended Data Fig. 7f, g ), suggesting its potentials in 249 tumor therapies. 250
DISCUSSION 251
The adjuvant activity of Aluminum was found by Alexander Glenny and his colleagues in 1926 41 , 252 now almost one century later, we reported the adjuvant activity of another metal-Manganese. 253
Adjuvant effect is essentially attributed by type I-IFN-promoted dendritic cell maturation and 254 migration to prime adaptive immune responses along with 1) local up-regulation of chemokines, 255
including CCL2 (MCP-1) and CCL3 (MIP-1α) to recruit immune cells to the injection site; 2) 256 increase of antigen uptake by immune cells; 3) induction of monocyte differentiation into dendritic 257 cells 8, 36, 37 . We found that Mn 2+ induced APCs to produce both IFNβ and various IFNαs, which 258
were surprisingly not induced by LPS, together with many co-stimulatory and MHC molecules 259 crucial for antigen presentation and chemokines for immune cell recruitment. MnJ also strongly 260 enhanced antigen uptake by APCs and the differentiation of monocytes to dendritic cells. 261
Importantly, Mn 2+ did not induce the production of pro-inflammatory cytokines IL-1 and IL-18 in 262 human or mouse in vitro and in vivo. Therefore, MnJ demonstrated superior adjuvant effects as it 263 induces humoral, cellular, and mucosal immune responses, particularly CTL activation, without 264 detected side-effects. In addition, the adjuvant effect of MnJ was stable even after repeated 265 freeze-drying cycles, whereas Alum is sensitive to freezing and requires cold-chain temperature 266 control 42,43 . MnJ showed great adjuvant effects to all tested vaccine antigens including inactivated 267 viruses, recombinant protein subunits and peptides, thus it can significantly reduce the amount of 268 viruses needed. Particularly, its tumor antigen-specific CTL activity by either intramuscular or 269
intranasal MnJ immunization indicated a great potential for cancer vaccines. Based on these results, 270
we believe that MnJ has great potentials for the development of potent but safe vaccines. The 271 component simplicity and steadiness of MnJ, the low cost and wide availability of Mn make this 272 adjuvant even more promising. 273
Although Alum adjuvanted vaccines have been proven to be safe in most cases, some studies 274 showed that aluminum accumulation are associated with long-lasting macrophagic myofasciitis 275 (MMF) 44 , nervous disoders 45 and bone disease 46 in some patients. The FDA-approved doses of 276 850 μg, 1140 μg, and 1250 μg Alum per vaccine were determined according to antigenicity and 277 effectiveness of vaccine, not including safety consideration [47] [48] [49] . After vaccine injection, Alum has 278 been found in the injected muscle, draining lymph nodes and spleen 9 months in humans 50 or even 279 12 years in patients with ASIA (Autoimmune/inflammatory syndrome induced by adjuvants) 51, 52 . 280
Consistently, we found that intramuscularly injected Alum in mice did not show obvious clearance 281 2 weeks after injection whereas injected MnJ was beyond detection after 8 days. Importantly, MnJ, 282
but not Alum, could be readily decomposed into free Mn 2+ ions by many common acidic metabolic 283 products or under acidic environment (data not shown). In addition, tumor microenvironment is 284 characterized by anomalous metabolic properties and acidic environment 53 , which might be 285 beneficial for the application of MnJ in antitumor therapy. Excessive Mn accumulation in the 286 central nervous system causes neurologic toxicity in occupational cohorts through inhalation from 287 welding or smelting 26 . However, we found that 20 μg MnJ induced higher antibody production 288 than 1444 μg Imject® Alum, 1444 μg Alhydrogel® adjuvant 2%, 2259μg Adju-Phos® adjuvant 289 (500 μg Alum in each) did, indicating MnJ is at least 25 times more potent than Alum in terms of 290 inducing humoral immune response, which means that much smaller amount of MnJ can achieve 291 the same effect. 292
There is still controversy about the function of NLRP3 inflammasome on adjuvant effect of 293 aluminum salt 12 . These different conclusions may result from different aluminum salts or mice 294 backgrounds used. There is also another view that ASC has an inflammasome-independent role in 295 shaping adaptive immunity, for regulating the expression of Dock2, which is important for antigen 296 uptake and lymphocyte mobility 38 . However, we found that STING, NLRP3 or ASC deficiency 297 did not affect the expression of Dock2 in macrophages or lymphocytes. Interestingly, manganese 298 salts administration did not upregulate pro-IL-1β or pro-IL-18 production, which means that MnJ 299 activate adaptive immune responses partly through an inflammasome-dependent but inflammatory 300 cytokines-independent manner. In this regard, there may be some other stimulators upregulated by 301
MnJ and released by pyroptotic death of cells. However, even though we did not detect IL-1/-18 302 production by macrophages or PBMCs treated with MnCl2 alone, these cells may generate these 303 cytokines when treated with inactivated pathogens plus MnCl2. IL-1 and IL-18 can promote the 304 infiltration of neutrophils and enhance immune responses after immunization with adjuvants like 305 Alum or ISCOMATRIX 40, 54, 55 . 306
In addition, similar to Alum adjuvant, the MnJ nanoparticles were also able to absorbe antigens 307 like OVA, GFP or PE proteins (data not shown). The physical depot effect of MnJ retained antigens 308 at the injection site and enhanced the uptake of antigens by APCs. Generally, MnJ is an adjuvant 309 owning the properties of both immune potentiator and delivery system. Because of its excellent 310 adjuvant activities and stability against repeated freezing-thaw treatment, Mn-based adjuvants 311 would be especially useful in veterinary vaccines with the following three additional advantages. 1) 312
MnJ showed a very nice dose-dependent adjuvant activity intramuscularly or intranasally, with 20 313 μg MnJ per mouse showing stronger antibody inducing activity than any tested adjuvants including 314 CFA; 2) High MnJ dose (up to several mg/shot) and repeated administrations to mice, rabbits or 315 pigs (data not shown) did not cause any visible damage or inflammation such as swellings and 316 granulomas at the injection sites or in various organs; 3) Mammals keep tissue Mn levels via tight 317 control of both absorption and excretion, as normally only 1-5% of ingested Mn is absorbed into 318 the body 56 and excessive dietary Mn causes reduced Mn absorption and enhanced Mn metabolism and excretion 57-59 . Therefore, even highly elevated Mn levels in meats caused by Mn-containing 320 veterinary vaccines would unlikely increase gastrointestinal Mn absorption by humans. In fact, Mn 321 contents in whole grains, rice, and nuts are around or more than 30 mg Mn/kg or even 110-140 mg 322
Mn/kg in wheat bran, much higher than those in mammals that are between 0.3 and 2.9 mg Mn/kg 323 wet tissue weight, confirming the tight Mn absorption by animals. and cell biology 82, 488-496, doi:10.1111/j.0818-9641.2004.01272.x (2004) . for new generation vaccine antigens: alliance has its own advantage. Artif Cells Nanomed 334
Biotechnol 46, S818-S831, doi:10.1080/21691401.2018.1513941 (2018 3755-3759, 350 doi:10.4049/jimmunol.181.6.3755 (2008) . 1390-1394, doi:10.1126/science.1244040 (2013) . Sensor cGAS-STING-Dependent Induction of Type I Interferons. Immunity 44, 597-608, 386 doi:10.1016/j.immuni.2016.02.004 (2016) . 387 activation. The Journal of experimental medicine 214, 3611-3626, doi:10.1084/jem.20171749 404 (2017) . immunoblotting with the indicated antibodies (d). Human IL-1β and IL-18 in supernatants were 537 analyzed by ELISA (e). One representative experiment of at least three independent experiments is 538 shown, and each was done in triplicate. Error bars represent SEM; a, data were analyzed by an 539 unpaired t test. ns, not significant; * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. 540 intramuscularly with PBS or OVA (10 μg) + MnJ (0, 2, 5 or 10 μg) on day 0, 7 and 14. Sera were 543 collected on day 21 to measure OVA-specific IgG1 by ELISA (left, n = 5). Time course of 544 OVA-specific IgG1 in sera from mice immunized intramuscularly with OVA (10 μg) + MnJ (10 μg) 545 for three times (right, n = 3). b, c, The WT mice were immunized intramuscularly with PBS, OVA 546 (10 μg), OVA (10 μg) + MnJ (5 μg) or OVA (10 μg) + indicated amounts of Aluminium salts. Sera 547 were collected on day 21 to measure OVA-specific IgG1 by ELISA (b) (n = 4). OVA-specific 548 cytotoxicity was measured on day 21 in an in vivo killing assay (c) (immunized on day 0, 7 and 14, 549 n = 4). d, The WT mice were immunized intramuscularly with the indicated antigen (5 μg), antigen 550 (5 μg) + MnJ (10 μg) or antigen (5 μg) + Alum (1320 μg) on day 0, 7 and 14. Sera were collected 551 on day 7, 14 and 21 to measure HA1, NP, EV71, HBsAg or HBSS1-specific IgG total (n = 3). e, 552
The WT mice were immunized intranasally with PBS or OVA (10 μg) + MnJ (0, 1, 2 or 5 μg) on 553 day 0, 7 and 14. Sera were collected on day 21 to measure OVA-specific IgA by ELISA (left, n = 554 5). Time course of OVA-specific IgA in BALF, saliva and serum as indicated from mice 555 immunized intranasally with OVA (10 μg) + MnJ (5 μg) for three times (n = 3). f, OVA-specific 556
IgA and IgG total were measured by ELISA on day 21 after immunization with OVA (10 μg), OVA 557 (10 μg) + MnJ (5 μg) or OVA (10 μg) + CTB (10 μg) intranasally on day 0, 7 and 14 (n = 3). One 558 representative experiment of at least three independent experiments is shown, and each was done 559 in triplicate. Error bars represent SEM; d, data were analyzed by two-way ANOVA; a, e, f, data 560
were analyzed by an unpaired t test. ns, not significant; * P < 0.05; ** P < 0.01; *** P < 0.001; 561 **** P < 0.0001. 562 Tmem173 −⁄− Pycard −⁄− and Tmem173 −⁄− Nlrp3 −⁄− mice were measured by ELISA on day 14 after 590 immunization with OVA (10 μg) or OVA (10 μg) + MnJ (10 μg) intramuscularly on day 0 and 7 (n > 591 5). c, OVA-specific IgA from the WT, Tmem173 −⁄− , Pycard −⁄− and Tmem173 −⁄− Pycard −⁄− DKO mice 592 was measured by ELISA on day 21 after immunization with OVA (10 μg) or OVA (10 μg) + MnJ 593
